Stocktwits on MSN
Novocure stock surges nearly 30% after hours: FDA clears first new pancreatic cancer therapy in almost three decades
The FDA approved Optune Pax for locally advanced pancreatic cancer. ・The Panova-3 trial showed Optune Pax, used alongside ...
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users ROOT, Switzerland--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug ...
(1) Optune Lua includes both active patients in NSCLC and MPM. Worldwide, there were 39 and 32 active MPM patients on therapy as of September 30, 2025 and 2024 and 100 and 1 active NSCLC patient(s) on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results